This research introduces the development of controlled release lumiracoxib gels that are effective when applied topically. The study examines the potential of these gels as carriers for delivering lumiracoxib. The in-vitro drug release pattern of all formulations demonstrated diffusion-controlled release following a zero-order pattern. Additionally, all formulations were determined to be compatible with the skin and stable according to the ICH guidelines. The optimized lumiracoxib gel exhibited a significant reduction in paw edema, reaching up to 79.51% after 6 hours. However, it was observed to have no significant effect on inhibiting 5- lipoxygenase, even with higher doses. Based on the findings, the lumiracoxib gel containing 0.5 g of Carbopol was identified as the optimized formulation for treating local inflammation